Gene Polymorphisms of FABP2, ADIPOQ and ANP and Risk of Hypertriglyceridemia and Metabolic Syndrome in Afro-Caribbeans

Abstract

ObjectivesThe metabolic syndrome (MetS) is a cluster of metabolic abnormalities and cardiovascular risk factors that are highly heritable and polygenic. We investigated the association of allelic variants of three candidate genes, rs1799883-FABP2, rs1501299-ADIPOQ and rs5065-ANP with MetS and its components, individually and in combination, using a genetic risk score.MethodsA cross-sectional study was conducted in 462 Afro-Caribbeans subjects without cardiovascular complications or lipid-lowering medications. Cardiovascular risk factors and MetS components (NCEP-ATPIII criteria) were recorded. The 3 SNPs were genotyped. The genetic risk score was calculated by summing the number of risk alleles at each locus. Logistic regressions were used.ResultsFifty-eight participants (12.6%) were diabetics and 116 (25.1%) had a MetS. In a dominant model, rs1799883 was associated with hypertriglyceridemia (OR 2.22; P = 0.014) and hypertriglyceridemic waist (HTGW), (P = 0.014) but not significantly with overweight (P = 0.049), abdominal obesity (P = 0.033) and MetS (P = 0.068). In a dominant model, the OR of MetS and HTGW for rs1501299 were 1.80 (P = 0.028) and 2.19 (P = 0.040) respectively. In a recessive model, the OR of hypertriglyceridemia for rs5065 was 1.94 (P = 0.075). The genetic risk score was significantly associated with MetS. Subjects carrying 4–5 risk alleles (18.8%) had a nearly 2.5-fold-increased risk of MetS compared to those carrying 0–1 risk allele (24.3%): OR 2.31; P = 0.025.ConclusionsThis study supports the association of FABP2, ANP and ADIPOQ gene variants with MetS or its components in Afro-Caribbeans and suggests a cumulative genetic influence of theses variants on this syndrome and a potential effect on lipid metabolism.

Polymorphism in Apolipoprotein C3 (APOC3) and Fatty Acid-Binding Proteins (FABP2) Genes in Nondiabetic Dyslipidemic Patients: A Tertiary Care Hospital-Based Pilot Study

“…6 A gene associated with TG and CHOL level is the gene encoding for fatty acid-binding proteins (FABP2) located at the chromosome 4q2-q31, another gene apolipoprotein C3 gene (APOC3) located on the chromosome 11q23, allele *3238 C is also involved in the regulation of plasma TG levels. 7,8 The circulating lipid biomarkers, mainly polymorphism APOC3 (rs5128) and FABP2 (rs1799883), had been independently studied in diabetic patients, but the associations between these biomarkers and occurrence of dyslipidemia in nondiabetic patients had rarely been studied. There is no information regarding the genetic influence of dyslipidemia and their relations with biochemical estimations of circulating lipoproteins in the population representing Bhopal city (Central India).…”

“… 6 A gene associated with TG and CHOL level is the gene encoding for fatty acid-binding proteins ( FABP2 ) located at the chromosome 4q2–q31, another gene apolipoprotein C3 gene ( APOC3 ) located on the chromosome 11q23, allele *3238 C is also involved in the regulation of plasma TG levels. 7 8 …”

The T2238C Human Atrial Natriuretic Peptide Molecular Variant and the Risk of Cardiovascular Diseases

“…Several case-control association studies were performed in the attempt to explore the pathological relevance of the T2238C transition. As a result, an association of the C2238 allele with an increased risk of both myocardial infarction and stroke was reported in different cohorts, including Caucasian and Asian populations [ 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 ]. Moreover, carriers of this variant allele showed an increased risk of recurrent ischemic stroke and of myocardial infarction [ 16 , 18 ].…”

Συσχέτιση Της Παχυσαρκίας Με Πολυμορφισμούς Γονιδίων Σε Δείγμα Ελληνικού Πληθυσμού

“…κυτοσίνης με μια γουανίνη. Σύμφωνα με την βιβλιογραφία, σε περίπτωση που το αλληλόμορφο γονίδιο που φέρει την γουανίνη στο συγκεκριμένο σημείο, εμφανίζεται έστω και μια φορά στον γονότυπο, τότε υπάρχει μειωμένη πιθανότητα εμφάνισης τόσο διαβήτη και παχυσαρκίας, όσο και κάποιων μορφών καρκίνου, όπως αυτός του παχέως εντέρου.Γονίδιο FABP2 / rs1799883[86,87] Η ανάλυση και η παράθεση των αποτελεσμάτων του γονιδίου έχει πραγματοποιηθεί στην ενότητα 2.3.9, που αφορά στον μεταβολισμό των λιπιδίων [91,92]. Η πρωτεΐνη που κωδικοποιείται από το συγκεκριμένο γονίδιο, είναι το πρόδρομο μόριο του αγγειοτενσινογόνου, το οποίο εκφράζεται στο ήπαρ και κόβεται από το ένζυμο ρενίνη, με στόχο της μείωση της πίεσης του αίματος.…”